⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OVID News
Ovid Therapeutics Inc. Common Stock
Form 8-K
sec.gov
ATNM
CRMD
OVID
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
prnewswire.com
CRMD
OVID
ATNM
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
prnewswire.com
HBIO
SLNO
BMB
ACAD
JAZZ
IONS
OVID
PTC
SRPT
MAR
NVS
LLY
PFE
Ovid Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
OVID
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight
globenewswire.com
BIIB
HRMY
XNCR
AZN
LLY
PFE
REGN
NVS
TSLA
TAK
GSK
JNJ
UCB
BHF
PRAX
XENE
AQST
TNDM
INCY
MRK
ABBV
BMY
AMGN
GILD
VRTX
CRSP
EDIT
NTLA
SRPT
ALNY
EXAS
TEVA
AXSM
CYTK
INSM
KODK
LPCN
MNKD
NBIX
NCLH
ONCY
ORIC
PBYI
PEGA
PLRX
PRGS
QGEN
RGNX
ROST
RYAAY
SNOW
SWKS
SYK
TGT
TRMB
TXG
ULTA
VRSK
WDC
WVE
XOM
ZBRA
ZNTL
ZTS
STOK
IONS
MOMO
BBAR
CTXR
MBIO
GNS
NEON
OVID
BHVN
Form 8-K
sec.gov
OVID
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
globenewswire.com
OVID
Form 8-K
sec.gov
OVID
CERO
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
globenewswire.com
OVID
BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum
globenewswire.com
OVID